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Uwe Platzbecker,1 Johannes Schetelig,1 J€urgen Finke,2 Rudolf Trenschel,3
Bart L. Scott,4 Guido Kobbe,5 Kerstin Schaefer-Eckart,6 Martin Bornh€auser,1
Raphael Itzykson,7 Ulrich Germing,5 Dietrich Beelen,3 Gerhard Ehninger,1 Pierre Fenaux,7
H. Joachim Deeg,6 Lionel Ades,7 on behalf of the German MDS Study Group, Cooperative
Transplant Study Group, Fred Hutchinson Cancer Research Center, and Groupe Francophone
des MyelodysplasiesStandard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS) includes hypo-
methylating agents, such as azacitidine (AZA). However, the only approach with curative potential remains
allogeneic hematopoietic cell transplantation (HCT). To date, no direct comparison of both strategies has
been reported. The outcomes of 2 well-balanced cohorts of patients with high-risk MDS defined by age
(60-70 years), performance status (Eastern Cooperative Oncology Group score#2), and donor availability
(yes/no) were compared, including 103 patients undergoing HCT and 75 patients without this option who
received AZA. The estimated 2-year overall survival after the start of treatment was 39% (95% confidence
interval, 30%-50%) for the patients undergoing HCT and 23% (95% confidence interval, 14%-40%) for the
patients receiving AZA therapy. In a multivariate Cox regression analysis of all patients (n 5 178), Eastern
Cooperative Oncology Group score (0 versus 1 versus 2; hazard ratio [HR], 2.9/3.9; P\ .001), cytogenetics
(good versus intermediate versus poor; HR, 1.2/1.7; P 5 .026), and treatment (HCT versus AZA; HR, 0.3;
P 5 .007) were associated with overall survival. This retrospective cohort analysis suggests a survival
advantage for allogeneic HCT compared with AZA therapy in medically fit patients with high-risk MDS
age 60-70 years. Prospective controlled studies are warranted.
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Myelodysplastic syndrome (MDS) occurs primar-
ily in older individuals, in whom treatment with
hypomethylating agents (HMA) such as azacitidine
(AZA) is associatedwith a survival advantage compared
with patients treated with supportive care [1,2].
However, the only therapy with proven curative
potential remains allogeneic hematopoietic cell
transplantation (HCT) [3]. Published data on the use
of allogeneic HCT in older patients with high-risk
MDS have been limited until recently. Many of these
patients were not considered viable candidates for allo-
geneic HCT because of concerns about increased
transplantation-related toxicity and excessive non-
relapse mortality (NRM), a challenging problem espe-
cially in older individuals. Because the extramedullary1415
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significantly to early NRM, the development of
reduced-intensity conditioning (RIC) regimens and
the use of alternative donor sources has allowed the
successful application of HCT in older patients with
MDS and acute myelogenous leukemia (AML) [4].
Today, considerable evidence suggests that alloge-
neic HCT can be successful in older patients with
MDS [5-8] and conceivably confers a survival
advantage compared with supportive care only and
other nontransplantation approaches [9]. To date, no
controlled prospective data are available, and no direct
randomized comparison of efficacy between HCT and
HMA therapy has been published [10]. Given the het-
erogeneity of MDS, the potential complications asso-
ciated with HCT, and the availability of therapeutic
nontransplantation alternatives such as HMA therapy,
determining when and in whom to perform allogeneic
HCT remains difficult for both patients and treating
physicians. In fact, a recent retrospective analysis dem-
onstrated that, in contrast to younger patients with
MDS, a survival benefit might be conferred in
higher-risk patients with MDS only with a certain de-
lay after HCT compared with HMA therapy [11]. Al-
though retrospective studies are subject to selection
bias, they can provide important information to facili-
tate clinical decision making [12]. Thus, we analyzed
treatment outcomes in a well-defined group of patients
age 60-70 years with de novo high-riskMDS undergo-
ing allogeneic HCT, and compared these outcomes
with those observed in a similar cohort of patients
who had received first-line treatment with AZA in
the absence of a suitable donor for HCT.MATERIALS AND METHODS
Study Design
The participating transplant centers in Germany
and the United States (German MDS Study Group
[GMDS-SG], German Cooperative Transplant Study
Group [GCTSG], Fred Hutchinson Cancer Research
Center [FHCRC]) provided data on patients age 60-70
years who underwent allogeneic HCT with an initial
diagnosis of high-risk MDS, defined as refractory ane-
mia with excess of blasts (RAEB), RAEB in trans-
formation (RAEB-t), or chronic myelomonocytic
leukemia (CMML) according to the French-
American-British (FAB) classification system or as
INT-2/HIGH risk MDS according to the Interna-
tional Prognostic Scoring System (IPSS) [2]. The anal-
ysis was restricted to patients with RAEB, RAEB-t, or
CMML and at least 5%marrow blasts at diagnosis, be-
cause these disease categories generally would be con-
sidered indications for HCT in younger individuals.
Only patients who received at least intermediate-
intensity conditioning (excluding those conditionedwith fludarabine plus 2 Gy TBI) and patients with an
Eastern Cooperative Oncology Group (ECOG) score
\3 were included, to avoid a selection of medically un-
fit patients with comorbidities that presumably would
exclude them from consideration for intensive treat-
ment approaches, including allogeneic HCT.
The HCT cohort was compared with a French
cohort of patients who had received AZA treatment
and did not undergo allogeneic HCT, either because
of the lack of a suitably HLA-matched donor or
because the patient was not considered for HCT by
the treating physician in accordance with guidelines
that preclude offering HCT to patients with high-
risk MDS age .60 years. As for the HCT cohort,
the analysis was restricted to patients age 60-70 years
with $5% blasts (RAEB, RAEB-t, or CMML) in the
bone marrow at the time of diagnosis. Data were pro-
vided by the registry of the Groupe Francophone de
Myelodysplasie, which currently contains information
on 735 patients who received at least 1 cycle of AZA
and were treated at 42 French centers, including 282
patients with IPSS INT-2/HIGH-risk MDS and
RAEB-t, as described previously [13].
Definitions
Patientswere also classified according to theWorld
Health Organization (WHO) system. Cytogenetic
subgroups and RBC transfusion dependency were de-
fined according to the IPSS and WHO classification–
based scoring system [2,8]. Conditioning regimens
were defined based on criteria of the European
Group for Blood and Marrow Transplantation as
conventional-intensity conditioning with myeloabla-
tive intent [14] or as RIC.
Response criteria and parameters for progression
were assessed according to the International Working
Group (IWG) [15]. Event-free survival (EFS), with
event defined either as death, relapse or progression,
and overall survival (OS) times were calculated from
start of treatment (AZA versus HCT). Both relapse
and progression were considered in the calculation of
relapse incidence. The definition ofNRMas a compet-
ing event for relapse incidence was applied to both
HCT and AZA therapy, as described by Cheson
et al. [15]; however, patients with complete remission
(CR), partial remission (PR), hematological improve-
ment (HI), stable disease (SD) in response to AZA
were considered to have NRM.
Statistical Methods
Estimates for OS and EFS were calculated using
the Kaplan-Meier method. The log-rank test was
used for univariate comparisons. Incidents of relapse/
progression and NRM were calculated using
competing-event statistics, and the Gray test was
used for univariate comparisons [16]. Approximate
95% confidence intervals (CIs) are provided for point
Biol Blood Marrow Transplant 18:1415-1421, 2012 1417Allo HCT in Older MDSestimates of OS, EFS, relapse incidence, and NRM.
Variables for the multivariate analysis were selected
a priori based on literature data, to ensure that the es-
timated treatment effects were adjusted for the most
important confounders. Survival data were censored
at 3 years after the start of treatment. Complete case
analyses were performed. The proportional hazards
assumption was checked for each multivariate model
by analyzing the scaled Schoenfeld residuals [17].
Cox regression models were fitted for OS and EFS.
Age, interval from diagnosis to treatment, ECOG
score, WHO classification, cytogenetic results, and
type of treatment were entered into the multivariate
model. Scaled Schoenfeld residuals were analyzed to
check the proportional hazards assumption for the
Cox regression models for OS and EFS. The global
tests for a change of the hazard rates over time indi-
cated nonproportionality for both models (P 5 .02
for the Cox model for OS and P 5 .002 for the Cox
model for EFS). Further analysis indicated that
this was the result of variations in the treatment effect
(AZA versus HCT) over time (data not shown).
Scaled Schoenfeld residuals can be interpreted as
time-dependent b coefficients. Larger values of these
residuals with increasing observation times indicated
an increasing hazard rate for patients in the AZA group
compared with the HCT group. The systematic
deviation of the smoothing splines from a horizontal
line is indicative of nonproportional hazards in the 2
treatment groups. Proportional hazards are a basic as-
sumption for Cox regression analysis, however.
Because proportionality of the hazard could not be
assumed for this simple model, a dichotomous time-
dependent covariate was introduced into the Cox
model, which allowed for the calculation of different
treatment effects in the first year after the start of treat-
ment (AZA or HCT) and the subsequent time period.
Computations were done with SPSS version 18.0.0
(IBM, Armonk, NY) and R version 2.12.1 (IBM,
Armonk, NY), including the software packages for
survival (2.36-5) [18,19]. This retrospective study was
performed according to the Declaration of Helsinki.
All patients provided informed written consent for
participation in research studies, and the use of data
of the MDS registry was approved by the Institutional
Review Boards of the University of Dresden and the
Fred Hutchinson Cancer Research Center, as well as
by the Groupe Francophone de Myelodysplasie.RESULTS
Characteristics of the Study Cohorts
HCT cohort
A total of 103 patients with de novo high-riskMDS
who underwent HCT between 1995 and 2008 wereidentified at participating centers. As shown in
Table 1, all patients had RAEB, RAEB-t, or CMML,
and 67 of them (65%) met the criteria for IPSS
INT-2/HIGH risk. Forty-two patients (41%) had
received induction chemotherapy (CR rate, 39%); 6
patients (6%) had received various treatments, includ-
ing an erythropoiesis-stimulating agent or HMA alone
(3 of whom achieved hematologic improvement and 3
of whom had stable disease); and 51 patients (49%)
received supportive care only.
Marrow blast counts ranged from 5% to 30% (me-
dian, 11%) at the time of diagnosis and from 0%-80%
(median, 10%) before HCT. The pretransplantation
HCT Comorbidity Index (HCT-CI) could be deter-
mined in 94 patients; the score was 0 in 37 patients
(39%), 1 in 16 patients (17%), 2 in 16 patients (17%),
and $3 in 25 patients (27%) [20].
AllogeneicHCTwas performed at 1.3-112months
(median, 7.6 months) after the diagnosis of MDS.
Sixty-one patients (59%) received an RIC regimen
and 45 (41%) received a conventional-intensity condi-
tioning regimen, followed by transfusion of peripheral
blood stem cells (n 5 94) or bone marrow (n 5 4)
(information missing on 5 patients) from an unrelated
donor (n 5 63; 61%) or a related donor (n 5 40;
39%) without further manipulation. The donor was
HLA-identical in 78 patients (76%) and single allele–
mismatched in 17 patients.
AZA cohort
Seventy-five patients were diagnosed between
2004 and 2009. The time from diagnosis to first-line
treatment with AZA ranged from 0 to 141 months
(median, 6 months). The marrow blast counts were
5%-30% (median, 12%) at diagnosis and 6%-59%
(median, 17%) before initiation of AZA therapy. A
search for a suitable (ie, at least a 9 of 10 allele match)
donor for HCT was initiated at the start of AZA ther-
apy for the majority (n 5 60; 80%) of patients but was
unsuccessful. In the other 15 patients (20%), HCTwas
not considered based on guidelines precluding alloge-
neic HCT for patients age .60 years.
Patients received a median of 6 cycles (range, 1-52
cycles) of AZA therapy. Only 6 patients received fewer
than 3 cycles of treatment. The cycles were limited be-
cause all patients exhibited early progression to higher-
stage MDS or AML. ECOG scores were not available
at the time of diagnosis for the AZA group, but was 0-
2 (median, 1) at the initiation of AZA therapy. Thirty-
four patients (45%) responded to AZA treatment with
CR, PR, or HI; 18 (24%) had stable disease; and 14
(19%) exhibited primary disease progression. The ex-
tent of response was unknown in 5 patients (7%), and
4 patients (6%) could not be evaluated because of early
death. Later in the course of disease, 16 patients (21%)
underwent induction chemotherapy because of no
response or progressive disease while receiving AZA.
Table 1. Disease and Patient Characteristics at Diagnosis and before Treatment
At Diagnosis Before Treatment
P AZA (n 5 75) HCT (n 5 103) P AZA (n 5 75) HCT (n 5 103)
Sex, male/female .95 55/20 76/27 .95 55/20 76/27
Age, years, median (range) .01 65 (56-70) 63 (54-69) .02 66 (60-70) 64 (60-70)
FAB, n (%) .33 <.01
RAEB 60 (80) 75 (73) 45 (60) 41 (40)
RAEB-T 11 (15) 16 (16) 21 (28) 10 (10)
AML 0 0 7 (9) 43 (42)
CMML 4 (5) 12 (12) 2 (3) 9 (9)
WHO, n (%) .18 <.01
RAEB-1/CMML-1 31 (41) 41 (40) 16 (21) 15 (15)
RAEB-2/CMML-2 30 (40) 49 (48) 31 (41) 28 (27)
AML 11 (15) 13 (13) 28 (37) 51 (50)
Unknown 3 (4) 0 0 9 (9)
IPSS, n (%) .78 <.01
INT-1 14 (19) 20 (19) 4 (5) 9 (9)
INT-2 30 (40) 36 (35) 29 (39) 23 (22)
HIGH 23 (31) 31 (30) 37 (49) 19 (18)
AML 0 0 0 43 (42)
Unknown 8 (11) 16 (16) 5 (7) 9 (9)
Cytogenetics, n (%) .78 .14
Good 37 (49) 53 (52) 28 (37) 51 (50)
Intermediate 10 (13) 16 (16) 12 (16) 16 (16)
Poor 23 (31) 25 (24) 32 (43) 28 (27)
Unknown 5 (7) 9 (9) 3 (4) 8 (8)
RBC TD, n (%) — <.01
Yes NA NA 42 (56) 73 (71)
No NA NA 16 (21) 28 (27)
Unknown NA NA 17 (23) 2 (2)
ECOG, n (%) — .06
0 NA 28 (27) 24 (32) 23 (22)
1 NA 43 (42) 38 (51) 70 (68)
2 NA 2 (2) 13 (17) 10 (10)
Time from diagnosis, months, median (range) — NA NA .10 6.0 (0-141) 7.6 (1.3-112)
NA indicates not available; RBC TD, RBC transfusion dependency.
Patients were grouped according to the current MDS classification and scoring systems, including FAB,WHO, IPSS, and cytogenetic risk groups defined
by the IPSS.
Bold text is significant.
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Characteristics at diagnosis
As shown in Table 1, at diagnosis the 2 patient
cohorts (HCT and AZA) were comparable in terms
of disease subtype (FAB or WHO), IPSS, and cyto-
genetic characteristics. There was no difference in
sex distribution, but the AZA group was slightly older
than theHCTgroup (median, 65 years versus 63 years;
P 5 .01).
Characteristics at onset of treatment
The cohorts were similar in terms of cytogenetic
risk, but the HCT cohort included more patients
with advanced disease (by FAB, WHO, or IPSS crite-
ria). In fact, the majority of patients in the HCT group
had progressed to a higher disease stage before HCT;
43 patients evolved to AML (42%) versus 7 (9%) in the
AZA group by the FAB criteria, and 51 (50%) versus 28
(37%) by theWHOcriteria. In addition,more patients
in the HCT group were RBC transfusion-dependent
(73 [71%] versus 42 [56%]; P\ .01). The 2 cohorts
showed no statistically significant difference in perfor-mance status or in the overall rate of induction chemo-
therapy (given only after AZA failure in the AZA
cohort) (Table 1).
Outcome
All patients undergoing HCT achieved primary
engraftment. With a follow-up of 7-154 months (me-
dian, 39 months) for surviving patients, the HCT
cohort had an estimated 2-year OS of 39% (95% CI,
30%-50%), 2-year EFS of 37% (95% CI, 28%-
48%), relapse rate of 30% (95% CI, 21%-39%), and
NRM of 33% (95% CI, 23%-42%). The 5-year OS
and EFS were 35% (95% CI, 26%-47%) and 36%
(95% CI, 27%-47%), respectively (Figures 1 and 2).
At last follow-up, 40 patients age 62-77 years (median,
68 years) were alive in remission after HCT.
With follow-up ranging from 1 month to 52
months (median, 13 months) from the start of AZA
therapy, the AZA cohort had a 2-year OS of 23%
(95% CI, 14%-40%), 2-year EFS of 14% (95% CI,
7%-27%), relapse/progression rate of 52% (95% CI,
40%-65%), and NRM of 34% (95% CI, 22%-45%)
(Figures 1 and 2). At last follow-up, 16 patients in this
Figure 1. OS and EFS among patients with MDS followed from the start of therapy according to treatment approach.
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months), age 62-70 years (median, 67 years), were alive.Multivariate Cox Regression Analysis of the
Total Cohort
The final models are shown in Table 2. ECOG
performance score and cytogenetics significantly con-
tributed to the prediction of OS and EFS. No effect onFigure 2. Stacked cumulative incidence curves from a competing-risks
model with relapse and death as competing risks, with the study
population substratified according to type of treatment: (A) AZA, (B)
HCT.OSwas detectable in the first year after initiation of the
intervention (hazard ratio [HR] for HCT versus
AZA, 1.3; P 5 .30), whereas after 1 year, HCT was
associated with a strong protective effect (HR, 0.3;
P 5 .007). The same pattern was observed for EFS.DISCUSSION
Our results demonstrate that HCTwas superior to
conventional treatment with AZA in achieving im-
proved long-term survival. However, the survival
curves of the 2 cohorts did not separate until approxi-
mately 2 years after the start of therapy, reflecting an
advantage for patients who underwent HCT only after
a delay post-HCT, which is consistent with a recent
analysis reported by Koreth et al. [11]. The delayed
separation of the curves was due at least in part to
NRM after allogeneic HCT related to GVHD and as-
sociated infectious complications. On the other hand,
NRM at 2 years was basically identical in the 2 cohorts:
34% (95% CI, 22%-45%) in the AZA group and 33%
(95% CI, 23%-42%) in the HCT group. Thus, our
data also suggest that, contrary to a common percep-
tion, NRM after HCT might not significantly exceed
mortality after conventional treatment with HMA.
Our findings also support the concept that chrono-
logical age alone should not serve as a barrier to alloge-
neic HCT in patients with advanced MDS who have
a suitable donor. However, in agreement with previous
reports of patients undergoing HCT or AZA, we con-
firmed the predictive value of patient performance sta-
tus on the probability of success of a given treatment
[7,13,20]. Until recently, supportive care was
considered the standard of treatment for most older
patients with high-risk MDS, with allogeneic HCT
restricted to aminority of patients, presumably selected
on the basis of biological age and fitness. New develop-
ments in disease-modifying agents and innovations in
allogeneic HCT have changed this paradigm [4,21-27],
Table 2. Multivariate Analysis of Factors Affecting 2-Year OS and EFS in the Total Cohort of Patients Undergoing Allogeneic HCT
(n 5 103) or Receiving AZATherapy (n 5 75)
OS EFS
HR 95% CI P HR 95% CI P
Age (continuous) 1.0 0.93-1.09 .90 0.99 0.92-1.07 .80
Time from diagnosis 0.94 0.84-1.06 .30 0.93 0.83-1.04 .20
Disease stage
RAEB-1/CMML-1 1 1
RAEB-2/CMML-2 1.4 0.7-2.6 .30 1.4 0.8-2.5 .30
RAEB-t/AML 1.5 0.8-2.8 .20 1.5 0.8-2.6 .20
ECOG score
0 1 1
1 2.9 1.6-5.1 <.001 2.3 1.4-3.9 .001
2 3.9 1.9-8.0 <.001 3.0 1.6-5.6 .001
Cytogenetics
Good risk 1 1
Intermediate risk 1.2 0.7-2.2 .45 1.3 0.7-2.2 .40
Poor risk 1.7 1.1-2.8 .026 1.7 1.1-1.6 .02
HCT versus AZA in the first year after initiation of treatment 1.3 0.8-2.3 .30 0.9 0.5-1.4 .60
HCT versus AZA from 1 year on 0.3 0.1-0.7 .007 0.4 0.2-0.97 .04
Bold text is significant.
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patients age .60 years undergoing allogeneic HCT.
Our data also demonstrate that allogeneic HCT, in
contrast to AZA treatment, can lead to long-term
disease control and possibly cure a substantial
proportion of patients with advanced MDS in the sev-
enth decade of life. In agreement with observations in
younger patients and recent retrospective analyses in
older patients with MDS who underwent allogeneic
HCT [6,7], high-risk cytogenetics was associated
with adverse outcome secondary to an increased inci-
dence of relapse [3,4,8,28,29]. Thus, relapse remains
a problem, primarily in patients with high-risk cytoge-
netics and a high blast count at the time of HCT.
A shortcoming of the present study is that we pre-
sumably cannot exclude a selection bias in the 2
cohorts analyzed. In addition, patients were matched
primarily for disease stage only at diagnosis, not at
the time of initiation of therapy. However, in light of
the fact that patients in the HCT group had more
advanced disease before HCT, their greater survival
benefit compared with the AZA cohort further sup-
ports our results. The worse median survival of our
AZA cohort compared with that reported in the
AZA001 study [1] is presumably a result of a regis-
try-based analysis, as well as major differences in pa-
tient characteristics, including more patients with
moderate performance status (32% with ECOG score
of 0 versus 44% in the AZA001 study) and poor risk
cytogenetics (43% versus 28% in the AZA001 study).
Patient groups were also matched for ECOG perfor-
mance status, but not for comorbidities according to
the HCT-CI, simply because such comorbidity scores
were not available for patients in the AZA group.
Thus, we cannot exclude the possibility that the pres-
ence of certain comorbidities in patients in the AZA
cohort might have dissuaded some patients and theirphysicians from pursuing a more aggressive manage-
ment strategy, including HCT. Nevertheless, two-
thirds of the HCT cohort had an HCT-CI score of 1
or higher, which argues against the possibility that
only totally medically fit patients underwent HCT.
Taken together, our findings suggest a benefit of
allogeneic HCT compared with AZA in older patients
with high-risk MDS or secondary AML. Although
these findings must be interpreted with caution, they
lead to the provocative hypothesis that HCT confers
a survival advantage to those patients, although our
data do not provide proof of superiority of HCT
over AZA. In particular, our analysis cannot be consid-
ered a true ‘‘donor versus no donor’’ comparison. The
inclusion of patients who had a donor identified but
did not undergo allogeneic HCT (eg, because of toxic-
ity related to previous therapy) might have further
strengthened our findings. Unfortunately, that infor-
mation was not available to us. Nevertheless, our inter-
pretation of the data is based on the assumptions that
the risk profiles of the 2 patient cohorts were captured
correctly, and that differences in outcome cannot be
explained by confounders that were not included in
themodel. Thus, we believe that this kind of retrospec-
tive analysis can still provide relevant clinical informa-
tion in the absence of prospective trials [12]. Given that
the common availability of HMA has led to changes in
HCT preparation regimens [30], future randomized
studies should evaluate allogeneic HCT preceded by
HMA therapy compared with HMA therapy alone in
older patients with high-risk MDS.ACKNOWLEDGMENTS
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